ScienceTop StoryTop StoryLatest News
Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
Sentiment: NeutralHigh Priority
What Happened?
A study of over 750,000 pregnancies found that women using Ozempic and Wegovy for diabetes had a higher risk of premature birth compared to those using them for weight loss.
Key points
- The study involved 756,636 pregnancies from 480,231 women.
- Women using GLP-1 medications for diabetes had a 70% higher risk of premature birth.
- No significant risk was found for those using the medications for weight management.
- The research was published in Human Reproduction Open.
- The study highlights the need for better guidance on GLP-1 medications during pregnancy.
Key insights
- The distinction between diabetes treatment and weight management is crucial for understanding pregnancy risks.
- Future studies should focus on the reasons for prescribing GLP-1 medications.
- The findings may lead to more personalized counseling for women inadvertently exposed to these drugs.
Why it matters
The findings could influence future medical guidance for women using GLP-1 medications during early pregnancy.
Tags
Entities
Ozempic· ProductWegovy· Productsemaglutide· Productliraglutide· ProductCopenhagen University Hospital Hvidovre· OrganizationDenmark· Country
Source
Science Daily
